Regulation and deregulation of cholesterol homeostasis: The liver as a metabolic "power station"

World Journal of Hepatology

Volumn 4, Issue 6, 2012, Pages 184-190

  Trapani, Laura ^a   Segatto, Marco ^a   Pallottini, Valentina ^a  

^a ROMA TRE UNIVERSITY   (Italy)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme a reductase; Cholesterol; Hypercholesterolemia; Liver; Low density lipoprotein receptors

Indexed keywords

EID: 84885911165     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v4.i6.184     Document Type: Article

References (52)

1. Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett 2006; 233: 10-15
2. Pasqualini JR. Enzymes involved in the formation and transformation of steroid hormones in the fetal and placental compartments. J Steroid Biochem Mol Biol 2005; 97: 401-415
3. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006; 174: 1124-1129
4. Martini C, Pallottini V. Cholesterol: from feeding to gene regulation. Genes Nutr 2007;2: 181-193
5. Weber LW, Boll M, Stampfl A. Maintaining cholesterol homeostasis: sterol regulatory element-binding proteins. World J Gastroenterol 2004; 10: 3081-3087
6. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu Rev Genet 2007; 41: 401-427
7. Trapani L, Pallottini V. Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective). Curr Gerontol Geriatr Res 2010; 2010:1
8. Segatto M, Trapani L, Marino M, Pallottini V. Age- and sex-related differences in extra-hepatic low-density lipoprotein receptor. J Cell Physiol 2011; 226: 2610-2616
9. Tolleshaug H, Hobgood KK, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: multiple mutations disrupt transport and processing of a membrane receptor. Cell 1983; 32: 941-951
10. Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 2008; 6: 447-470
11. Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev 2006; 86: 1237-1261
12. Al-Allaf FA, Coutelle C, Waddington SN, David AL, Harbottle R, Themis M. LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med 2010; 3: 36
13. Soutar AK. Rare genetic causes of autosomal dominant or recessive hypercholesterolaemia. IUBMB Life 2010; 62: 125-131
14. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-225
15. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104: 1-18
16. Vrablík M, Ceska R, Horínek A. Major apolipoprotein B-100 mutations in lipoprotein metabolism and atherosclerosis. Physiol Res 2001; 50: 337-343
17. Tai DY, Pan JP, Lee-Chen GJ.Identification and haplotype analysis of apolipoprotein B-100 Arg3500--> Trp mutation in hyperlipidemic Chinese. Clin Chem 1998; 44: 1659-1665
18. Durst R, Jansen A, Erez G, Bravdo R, Butbul E, Ben Avi L, Shpitzen S, Lotan C, Leitersdorf E, Defesche J, Friedlander Y, Meiner V, Miserez AR. The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients. Atherosclerosis 2006; 189: 443-450
19. Straniero S, Cavallini G, Donati A, Pallottini V, Martini C, Trentalance A, Bergamini E. Stimulation of autophagy by antilipolytic drugs may rescue rodents from age-associated hypercholesterolemia. Rejuvenation Res 2009; 12: 77-84
20. Trapani L, Violo F, Pallottini V. Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats. Exp Gerontol 2010; 45: 119-128
21. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175: 486-489
22. Rozman D, Monostory K. Perspectives of the non-statin hypolipidemic agents. Pharmacol Ther 2010; 127: 19-40
23. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy 2010; 30: 541-553
24. Kamanna VS, Bassa BV, Ganji SH. Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation. Life Sci 2008; 83: 595-601
25. Jin FY, Kamanna VS, Kashyap ML.Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999; 19: 1051-1059
26. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22: 24-36
27. Jin FY, Kamanna VS, Kashyap ML.Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997; 17: 2020-2028
28. Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM.Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000; 2: 64-71
29. Sharma R, Kaundal RK, Sharma SS. Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPAR gamma agonist in LPS-exposed guinea pigs. Pulm Pharmacol Ther 2009; 22: 183-189
30. Babiker A, Andersson O, Lindblom D, van der Linden J, Wiklund B, Lütjohann D, Diczfalusy U, Björkhem I. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J Lipid Res 1999; 40: 1417-1425
31. Lemieux I, Salomon H, Després JP. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann Med 2003; 35: 442-448
32. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-2273
33. Moutzouri E, Kei A, Elisaf MS, Milionis HJ.Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag 2010; 6: 525-539
34. Schneider A, Stange EF, Ditschuneit HH, Ditschuneit H. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 1985; 56: 257-262
35. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol 2007; 99: 3C-18C
36. Charlton-Menys V, Durrington PN. Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 2007; 67: 11-16
37. Ugawa T, Kakuta H, Moritani H, Inagaki O. Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. Br J Pharmacol 2002; 137: 561-569
38. Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. Endothelium 2007; 14: 239-243
39. Yamamoto S, Bloch K. Studies on squalene epoxidase of rat liver. J Biol Chem 1970; 245: 1670-1674
40. Ono T, Nakazono K, Kosaka H. Purification and partial characterization of squalene epoxidase from rat liver microsomes. Biochim Biophys Acta 1982; 709: 84-90
41. Ono T, Imai Y. Squalene epoxidase from rat liver microsomes. Methods Enzymol 1985; 110: 375-380
42. Sawada M, Matsuo M, Hagihara H, Tenda N, Nagayoshi A, Okumura H, Washizuka K, Seki J, Goto T. Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells. Eur J Pharmacol 2001; 431: 11-16
43. Ruf A, Müller F, D'Arcy B, Stihle M, Kusznir E, Handschin C, Morand OH, Thoma R. The monotopic membrane protein human oxidosqualene cyclase is active as monomer. Biochem Biophys Res Commun 2004; 315: 247-254
44. Fouchet MH, Donche F, Martin C, Bouillot A, Junot C, Boullay AB, Potvain F, Magny SD, Coste H, Walker M, Issandou M, Dodic N. Design and evaluation of a novel series of 2,3-oxidosqualene cyclase inhibitors with low systemic exposure, relationship between pharmacokinetic properties and ocular toxicity. Bioorg Med Chem 2008; 16: 6218-6232
45. Panini SR, Sexton RC, Gupta AK, Parish EJ, Chitrakorn S, Rudney H. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis by oxylanosterols. J Lipid Res 1986; 27: 1190-1204
46. Peffley DM, Gayen AK, KMorand OH. Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4'-(6-allyl-ethyl-amino-hexyloxy)-2'-fluoro-phenyl]-(4-bromophenyl)-me thanone (Ro 48-8071): comparison to simvastatin. Biochem Pharmacol 1998; 56: 439-449
47. Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009; 11: 67-70
48. Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007; 18: 397-400
49. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-1735
50. Gouni-Berthold I, Berthold HK. Antisense oligonucleotides for the treatment of dyslipidemia. Curr Pharm Des 2011; 17: 950-960
51. Song BL, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols. J Biol Chem 2006; 281: 25054-25061
52. Trapani L, Segatto M, Simeoni V, Balducci V, Dhawan A, Parmar VS, Prasad AK, Saso L, Incerpi S, Pallottini V. Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin. Biochimie 2011; 93: 1165-1171